Combining sponge spicules with Centella asiatica or hydroxyectoine raises several different questions. Can the ingredients coexist in the base? Is an active genuinely carried on the spicules? Does the finished combination perform better than its individual components? Each question needs different evidence.
Public patents describe Centella-treated or loaded spicules. That is a meaningful development lead, but it does not establish that ordinary mixing produces the same material. For hydroxyectoine, the literature reviewed here provides background on model membranes and cellular responses; it does not establish a directly tested synergy with commercial Hydrolyzed Sponge.
This review separates those evidence levels and proposes a programme for evaluating a defined combination. It is original editorial analysis by PINHON Active, which is associated with PINHONBIO. It does not report new laboratory work by this site or an independently verified PINHONBIO combination product.
Start by defining the combination
“Spicules with CICA” can describe a finished formula containing separate ingredients, a premix, a surface-treated powder or an impregnated material. These descriptions are not interchangeable.
For a conventional formula, the active may be distributed through the base without being attached to the needles. A coating or loading claim requires evidence about the processed particles themselves: what active is present, how much is associated with the material, and what remains associated during storage and use.
The same distinction applies to hydroxyectoine. Adding it to the aqueous phase does not demonstrate that the spicules carry it into skin. Better delivery and better tolerability are also separate endpoints; one cannot be inferred from the other.
What has been disclosed for Centella-loaded spicules?
VT CO LTD's patent application US20240408000A1 describes a Centella-containing spicule preparation and reports two-week human observations. Twenty participants completed the disclosed evaluation, which compared treated and untreated sites. This is original experimental disclosure by the applicant, rather than an independent peer-reviewed demonstration of ingredient synergy. US20240408000A1
Another patent publication describes purification and surface treatment involving Centella and shea butter. It provides additional evidence that processing, rather than simple co-presence, is central to some proposed combination systems. Its examples remain specific to the disclosed material and process. CN116553563A
These disclosures support investigating a defined loaded or treated material. They do not establish that any Centella extract mixed with any sponge powder reproduces the reported outcome, or that PINHONBIO supplies the disclosed technology.
A finished-product comparison also needs controls that can distinguish the contribution of the base, the spicules, the active and the processing route. A treated-versus-untreated comparison alone cannot resolve all of those contributions.
Centella extract and madecassoside need separate specifications
A combination study should identify exactly which Centella material is being used. A whole extract, a standardised triterpene fraction and isolated madecassoside do not define the same composition.
Record the marker compounds or assay that characterise the selected material, along with its solvent, carrier and other declared constituents. Compare its concentration on a relevant active-content basis when the project requires that comparison. An equal mass of two different commercial extracts does not establish equal amounts of their measured constituents.
Keep those specifications in the study record. If the extract changes, repeat the relevant compatibility and performance work rather than retaining the original conclusion under the general word “CICA”.
What does hydroxyectoine research contribute?
A molecular-dynamics study examined hydroxyectoine, water and DPPC lipid bilayers. It offers a mechanistic model for studying hydration-related interactions, rather than a clinical result for a spicule formula. The accessible arXiv version is a research manuscript, and should be identified as such. Smiatek et al., 2013 manuscript
Biological responses also depend on the test system. In a chronic-wound-fluid cell study, hydroxyectoine did not reverse the reported inhibition of keratinocyte proliferation and migration, and reduced adipose-derived stem-cell migration. This does not establish that hydroxyectoine is unsuitable for cosmetics; it prevents a blanket claim that every model demonstrates improved repair. Thamm et al., Int Wound J
Neither study tested a sponge-spicule combination. Within the sources reviewed for this article, no directly matched independent study was found establishing synergy between ordinary Hydrolyzed Sponge and hydroxyectoine. That is the limit of this search, not proof that no related work exists anywhere.
Hydroxyectoine and ectoine are different substances. Evidence for one should not be relabelled as evidence for the other without a specific scientific basis.
Compatibility, efficacy and synergy answer different questions
Compatibility asks whether the defined ingredients and base retain acceptable physical, chemical and microbiological properties under the tested conditions.
Combination efficacy asks whether the finished system produces a specified outcome compared with an appropriate control.
Synergy requires a defined interaction: the combined result must exceed the expectation established by a suitable model for the individual effects. A product performing better than an untreated site does not, by itself, establish synergy between two ingredients.
Choose the outcome and analysis before the experiment. A sensory preference result, a laboratory transport measurement and an irritation endpoint are different observations. They should not be combined into a single claim of “enhanced repair and delivery”.
A proposed controlled study for one active
Begin with a defined spicule lot, active material, base and application model. A useful starting design has four matched groups:
| Group | Composition | Question addressed |
|---|---|---|
| Vehicle | Base without the test spicules or active | What does the base contribute? |
| Spicules | Base plus the selected spicule material | What changes with the particles alone? |
| Active | Base plus the specified Centella material or hydroxyectoine | What changes with the active alone? |
| Combination | Base plus both at the matched study levels | Does the combination differ, and is there a supported interaction? |
Keep relevant carrier additions matched and document any unavoidable differences. Record the actual composition, rather than only the names of the ingredients. Use appropriate replication, allocation and statistical planning for the selected model.
Run separate studies for Centella and hydroxyectoine if the aim is to understand each pair with spicules. If the product contains all three and the claim concerns their interactions, an expanded design is needed to separate the two actives and their combined contribution. The four groups above cannot resolve every interaction in a three-component system.
These are proposed research designs. They do not specify a safe loading or constitute results for a PINHONBIO formulation.
Additional work for a coated-spicule claim
Compare the processed material with an ordinary physical mixture containing equivalent measured active and spicule amounts. Characterise both so that differences in needle geometry, residual carrier or processing are not mistaken for an active-loading effect.
A proposed analytical programme should address total active content, the fraction associated with the particles, unbound material and what happens after dispersion in the intended base. Select separation and assay methods that do not create the loading or release behaviour being measured.
Then examine retention or release under defined storage and test conditions. A loading result for dry powder does not establish that the active remains associated throughout the shelf life of an aqueous gel or emulsion. Microscopy can support morphology observations, but an image of needles alone does not quantify the active on them.
Evaluate the finished base and package
Compatibility testing should compare the blank, each component and the combination over time. Include the relevant active assays as well as pH, rheology, appearance, particle distribution and microbiological performance.
Check portion consistency in the intended package. If the active stays in the liquid phase while the particles settle, different portions may need further investigation even when the bulk composition was initially correct. Use observations and measurements to determine what happened rather than assuming a coating, binding or protective mechanism.
Record the incorporation route, mixing history, particle distribution and morphology alongside the compatibility results. This connects the evidence for the active with the behaviour of the actual particulate formula.
Keep claims within the tested endpoint
Before testing, define the intended use and the claim that the programme is meant to support. Avoid replacing a cosmetic evaluation with a promise of dermal delivery or treatment. Guangzhou's official cosmetics Q&A expressly addresses products whose action depends on needles entering skin rather than surface application. That boundary concerns how a product is intended to work, not merely which ingredient name appears on the label. Official Guangzhou Q&A, question 3
For a development concept without finished-product results, a useful statement is: “This programme will evaluate the compatibility and performance of a defined spicule–active combination.” Once results exist, state the material, formula, endpoint and conditions they support. Do not convert a patent example, a model-membrane study or a manufacturer's coating claim into a universal synergy claim.
Frequently asked questions
Is CICA mixed with sponge spicules the same as CICA-coated spicules?
No. Mixing establishes that both ingredients are present. A coating or loading claim requires analytical evidence for the processed material and its behaviour in the intended base.
Has hydroxyectoine been shown to remove spicule-related irritation?
The reviewed sources do not establish that result for a directly matched combination. It requires an appropriate study of the actual finished system; the separate ingredient's background literature cannot answer it.
Can a madecassoside result support every Centella extract?
The tested composition matters. Identify the extract, marker profile and carriers rather than treating all Centella-derived ingredients as equivalent.
Can a patent prove the combination is independently validated?
A patent may contain original experiments and useful development details. It remains applicant disclosure, and its design and controls still need critical appraisal.
For commercial ingredient information, consult the separately identified PINHONBIO pages for Hydrolyzed Sponge, Hydroxyectoine and Madecassoside. Their availability as individual ingredients is not evidence of a tested combination.
